Boundless Bio (BOLD) Q2 R&D Drops 17%

Boundless Bio (NASDAQ:BOLD), a biotechnology company developing targeted cancer therapies based on extrachromosomal DNA (ecDNA) biology, released its second quarter 2025 results on August 5, 2025. As expected for a pre-commercial biotech, Boundless Bio reported no revenue. The quarter showed a meaningful reduction in research and development expenses and continued progress in pipeline programs. Management reaffirmed that its $127.1 million in cash should fund operations into the first half of 2028. Source: Analyst estimates for the quarter provided by FactSet. Boundless Bio develops drugs that target ecDNA—a type of DNA found outside chromosomes within cancer cells. Its unique approach involves designing therapeutics aimed at treating oncogene-amplified cancers. These are aggressive tumors that standard treatments often fail to control.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool